GSK plc (NYSE:GSK) Shares Sold by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC lowered its position in GSK plc (NYSE:GSK) by 68.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 10,930 shares of the pharmaceutical company’s stock after selling 23,951 shares during the period. Mount Yale Investment Advisors LLC’s holdings in GSK were worth $370,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC increased its position in GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of GSK in the 2nd quarter valued at $52,487,000. Fisher Asset Management LLC lifted its position in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC boosted its position in GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after buying an additional 833,080 shares during the period. Finally, Bridgewater Associates LP boosted its holdings in GSK by 107.3% in the third quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock valued at $39,483,000 after purchasing an additional 500,010 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of GSK opened at $35.06 on Thursday. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The company’s fifty day moving average is $33.98 and its two-hundred day moving average is $37.75. The stock has a market capitalization of $72.67 billion, a P/E ratio of 22.77, a P/E/G ratio of 1.31 and a beta of 0.63.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GSK. StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Six investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.